Part D Rebates And Some New Health Policy Proposals Get Deficit Reduction Estimates In CBO Report
This article was originally published in RPM Report
Executive Summary
The most recent Congressional Budget Office list of deficit-reducing options includes some familiar items as well as five new approaches to changing health care programs, such as tax-related changes to employer-sponsored insurance.
You may also be interested in...
Part D Rebates: Talking Points Continue, But Deficit Deal Elusive
Once again the President is calling for rebates on prescription drugs sold under Medicare Part D. But without a big deficit deal involving entitlement reform, is there any way to enact them?
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.